STOCK TITAN

Avalyn Pharma (AVLN) Stock Price, News & Analysis

AVLN NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
30 142 sessions, April 30, 2026 to November 19, 2026
Largest daily move
-10.8% close of May 18, 2026
1-month change
+23% closing prices, October 19, 2026 to November 19, 2026

Company Description

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled medicines for serious, rare respiratory diseases. The company focuses on pulmonary fibrosis and other interstitial lung diseases, including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Its common stock is listed on the Nasdaq Global Select Market under the ticker symbol AVLN.

Avalyn's pipeline is built around inhaled formulations of established antifibrotic drug classes. Its lead programs include AP01, an inhaled formulation of pirfenidone, and AP02, an inhaled formulation of nintedanib. The company is developing these candidates for pulmonary fibrosis indications where treatment is directed at lung tissue affected by progressive scarring and impaired respiratory function.

The company's development model centers on targeted delivery of antifibrotic therapy through inhalation. Avalyn's research activities include clinical studies, quantitative lung imaging, patient-reported quality-of-life measures, supportive care research, and work on how patients and caregivers experience inhaled treatment. Company news has also described the use of high-resolution computed tomography imaging in AP01 research and the evaluation of AP01 delivery and supportive care experiences in pulmonary fibrosis.

Avalyn reports one operating and reportable segment: the business of developing and commercializing targeted therapies for rare lung diseases. As a clinical-stage biopharmaceutical company, its operating activities are concentrated on drug development, clinical program execution, product development, medical research, and preparations associated with potential commercialization of respiratory therapies.

Avalyn became a Nasdaq-listed public company following the closing of its initial public offering of common stock. Its public-company profile includes capital-structure matters related to its listed shares, governance updates related to its board and leadership structure, and operating updates tied to its AP01 and AP02 programs.

Stock Performance

$28.14
-1.95%
-0.56
After hoursChange vs the $28.70 closeLast updated: at
+23%
Performance 1 month

Avalyn Pharma (AVLN) closed at $28.70 on November 19, 2026. Over the past month, the price has gained 23.0%.

See what a $1,000 investment in AVLN would be worth today

Average down calculator for AVLN

AVLN Metrics & Rankings

Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

SEC Filings

Avalyn Pharma has filed 10 recent SEC filings, including 5 Form 4, 4 Form 144, 1 Form 10-Q. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all AVLN SEC filings →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
322,429
Shares Sold
18
Transactions
Most Recent Transaction
Baranowski Lyn (Chief Executive Officer) sold 7,200 shares at an average of $27.95 on November 18, 2026

Insider selling at Avalyn Pharma over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Avalyn Pharma has not filed a full fiscal year of results yet, so there are no annual figures to show here, and the quarterly figures it has reported so far are on its financials page.

Upcoming Events

DEC
01
December 1, 2026 Marketing

Evercore presentation

Presentation at Evercore on Dec 1 at 3:00 p.m. ET. Live webcast and archived recording available via the company investor site.
H2
2026
H2 2026 Clinical

AP03 Phase 1 start

Planned start of AP03 Phase 1 (inhaled pirfenidone+nintedanib fixed-dose combo) expected to begin by year-end 2026.
YEAR
2026
2026 Clinical

AP03 Phase 1 start planned

AP03 Phase 1 initiation planned by end-2026; IND/authorization dependent; company to provide start details and sites.
YEAR
2027
2027 Clinical

AURA AP02 topline data

Topline data for AURA Phase 2 AP02 expected in 2027; readout timing tentative; company to report topline results.
H2
2027
H2 2027 Clinical

Topline 12-month results

Topline 12-month results for AP01 Phase 2b MIST trial expected H2 2027; 375 patients enrolled; global FVC assessment.
H2
2027
H2 2027 Clinical

MIST topline data

Topline results from MIST Phase 2b (inhaled pirfenidone AP01) global trial; overenrolled to 398 patients; expected H2 2027.
H2
2027
H2 2027 Clinical

AP01 Phase 2b results

Topline AP01 Phase 2b results expected in second half 2027; key efficacy/safety readout for Avalyn Pharma Inc.'s program.
H2
2027
H2 2027 Clinical

AP03 Phase 1 results

AP03 Phase 1 healthy-volunteer trial results anticipated in second half 2027; topline safety and tolerability data for inhaled combo.
YEAR
2027
2027 Clinical

AURA topline results

AURA Phase 2 topline results expected late 2027 for a 12-week, two-dose, 160-patient placebo-controlled IPF trial.
YEAR
2027
2027 Clinical

AURA topline data

Topline data from AP02 AURA Phase 2 in idiopathic pulmonary fibrosis (160-patient trial) anticipated in late 2027.
YEAR
2027
2027 Clinical

AP02 Phase 2 results

AP02 Phase 2 results expected in late 2027 (Sep–Dec window); important efficacy/safety readout for Avalyn Pharma Inc.'s program.

Avalyn Pharma has 11 upcoming scheduled events. The next event, "Evercore presentation", is scheduled for December 1, 2026 (in 12 days). Investors can track these dates to stay informed about potential catalysts that may affect the AVLN stock price.

Short Interest History

Last 12 Months

Short interest in Avalyn Pharma (AVLN) currently stands at 2.3 million shares, down 2.2% from the previous reporting period, representing 5.7% of the float. Since May 2026, short interest has increased by 309.4%.

Days to Cover History

Last 12 Months

Days to cover for Avalyn Pharma (AVLN) currently stands at 5.3 days, down 20.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since May 2026, the figure has increased by 292.6%. Across the settlements charted above, it has ranged from 1.4 to 11.3 days.

AVLN Company Profile & Sector Positioning

Avalyn Pharma (AVLN) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing AVLN often look at related companies in the same sector, including Damora Therapeutics, Inc. (DMRA), Hemab Therapeutics Holdings, Inc. (COAG), Kailera Therapeutics, Inc. (KLRA), Generate Biomedicines, Inc. (GENB), and Ascentage Pharma Group International (AAPG). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate AVLN's relative position within its industry.

Frequently Asked Questions

The current stock price of Avalyn Pharma (AVLN) is $28.14 in after-hours trading as of November 19, 2026.

The market cap of Avalyn Pharma (AVLN) is approximately $1.3B. Learn more about what market capitalization means .

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled medicines for serious, rare respiratory diseases, with a focus on pulmonary fibrosis and other interstitial lung diseases.

Avalyn's main programs include AP01, an inhaled formulation of pirfenidone, and AP02, an inhaled formulation of nintedanib.

Avalyn focuses on pulmonary fibrosis indications, including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, as well as other interstitial lung diseases.

Avalyn reports one operating and reportable segment: developing and commercializing targeted therapies for rare lung diseases.

Avalyn operates as a drug-development company. Its activities center on clinical research, product development, and preparation for potential commercialization of inhaled therapies for rare lung diseases.

AP01 is Avalyn's inhaled formulation of pirfenidone being developed for pulmonary fibrosis indications.

AP02 is Avalyn's inhaled formulation of nintedanib being developed for pulmonary fibrosis indications.

Avalyn Pharma's common stock is listed on the Nasdaq Global Select Market under the ticker symbol AVLN.